Staff Writer

The FDA has granted approval to axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy, according to an announcement from the FDA.

Targeted therapy with tyrosine kinase inhibitors is necessary after surgery for patients with metastatic gastrointestinal stromal tumors with residual disease requiring resection to prevent disease recurrence.

According to real-world data, apalutamide may be more likely to offer an early and deep prostate-specific antigen reduction than enzalutamide.

FDA approval is being sought for dovitinib as a treatment option for patients with renal cell carcinoma.

Early results from a phase 1 study show promise for datopotamab deruxtecan for patients with advanced or metastatic triple-negative breast cancer.

Results shared in a webinar during the 2021 European Association of Urology Congress show the potential of adjuvant pembrolizumab for the treatment of renal cell carcinoma.

Findings from the S1619 trial signal that a neoadjuvant triplet is safe and effective for the treatment of resectable mesothelioma.

An update from KEYNOTE-365 trial shows the promising efficacy of olaparib in combination with pembrolizumab for patients with post-docetaxel metastatic castration-resistant prostate cancer.

Talimogene laherparepvec (T-VEC), an attenuated oncolytic virus, combined with pembrolizumab, an immune checkpoint inhibitor, passed an early safety evaluation for unresectable melanoma.

Two strategies of successive immunotherapy for the treatment of advanced melanoma recently showed similar safety and tolerability, yet substantially different efficacy.

Over a fifth of patients with previously treated advanced nasopharyngeal carcinoma showed a measureable response, when treated with pembrolizumab, an immune checkpoint inhibitor.

Failure-free survival (FFS) for patients with follicular lymphoma has had a lack of improvement, fueling interest in new treatment strategies that may offer promise for better outcomes.

Single-agent ibrutinib (Imbruvica) data showed durable responses in patients with untreated or relapsed/refractory chronic lymphocytic leukemia (CLL).

New combination strategies are required for heterogeneity of mantle cell lymphoma (MCL), in order to improve outcomes.

Clinical evaluation suggests a role for immune checkpoint inhibition in the treatment of patients with lymphomas, but early success has also raised many questions.

The treatment of TNBC continues to be a challenge for physicians because of its limited treatment options, the dearth of approved targeted therapies, high mortality, and poor prognosis.

While TNBC is a heterogeneous group of breast cancers there is increasing effort to subdivide it into more homogenous groups that may help in more accurate prognosis and response to therapy.

Breast cancer is a leading cause of cancer death in women, with 12% to 20% of cases classified as triple-negative breast cancer (TNBC).

Osimertinib (AZD9291), the third-generation TKI, demonstrated a 71% objective response rate (ORR) in those with EGFR T790M-mutant non-small cell lung cancer (NSCLC), following resistance to frontline anti-EGFR therapy.

Squamous cell lung cancer represents a distinct molecular pathologic NSCLC with unmet therapeutic needs, especially after failure of first-line platinum-based doublet chemotherapy.

Activation of T-cell function has become a main focus of immunotherapeutic approaches aimed at enhancing an anticancer immune response and suppressing mechanisms used by tumor cells for immune evasion.

Continued treatment with gefitinib (Iressa) beyond progression showed a trend toward better outcomes for those with T790M-negative non-small cell lung cancer (NSCLC).

Nivolumab (Opdivo) and ipilimumab (Yervoy), a chemotherapy-free regimen, showed activity as a first-line therapy for patients who have advanced non-small cell lung cancer (NSCLC).

The majority of patients under the age of 40 who have lung cancer had tumors with mutations that can be targeted with existing therapies.

Lung cancer is the leading cause of cancer-related mortality worldwide, with approximately 1.6 million deaths annually.

While the stage of bladder cancer is influential in determining treatment strategy, a number of other factors may also affect a patient’s treatment regimen.

There is a significant need for biomarkers throughout the course of bladder cancer diagnosis and different treatment regimens.

There are several agents currently in clinical trials for the treatment of bladder cancer.

Bladder cancer affects thousands of people in the United States.